Home » Twitter and AMD Options Stand Out, Is There A Double Top In Biotech?

twitter amd broadcom biotech

Twitter and AMD Options Stand Out, Is There A Double Top In Biotech?


Twitter and AMD Options Stand Out, Is There A Double Top In Biotech?

The stock market overall had another dull day, with the S&P 500 down less than 10 bps, closing at 2,747. Like I had mentioned yesterday, the S&P managed to hang around support at 2,746. Again, there is a chance we could try for 2,740, but my expectations continue to suggest higher equity price over the short-term.

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

S&p 500

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 731 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

Yields

10-year treasury yield continue to head lower, and I think they head toward the 2.6 percent region.

10-year


IBB

The NASDAQ Biotech ETF, $IBB, looks headed towards $111.50, where there is a steady level of support there. If that cracks, we have much lower to go, and it makes the downtrend more powerful.

biotech


XBI

The XBI looks scary now, and move to $93.50 nears. But the formation of what appears to be double top is what worries me. The only question, where is the neckline in this mess? It is probably not $93.50, and that is good news. It looks to be in a range of $88 or $89, and break below that would confirm the double-top, and a move much lower.

xbi

Regeneron

Regeneron continued its downward move today after getting close to resistance around $351.

regeneron

Biogen

Biogen continues to try to turn higher.

biogen

Advertisements

AMD

There was a lot of activity again in AMD options with 142,000 put contracts trading at $10 strike price for April 20 expiration. According to data from Trade Alert,  52 percent of the volume occurred on the bid, and that would tell me someone was likely buying the puts, but we won’t know until open interest updates tomorrow. There was already open interest of 267k contracts. Meanwhile, the $11 puts also traded about 43,000 contracts, but again the open interest going into today was about 265k.

The chart is near a major breakdown, and should it fall through $11.20, it is likely to head towards $10.70, but it could be as much as $9.75

amd

Advertisements

Broadcom

Broadcom reported better than expected fiscal first-quarter revenue of $5.331 billion, ahead of estimates for 4.998 billion, while beating on EPS at $5.12 per share versus estimates of $5.06 according to thefly.com. The guidance for revenue of $5 billion for the fiscal second quarter is pretty much in line with expectations. To me, after the first look, there was nothing in this report that wasn’t as expected. I think the overall trend in Broadcom continues to stay favorable, with the stock continuing to rise.

broadcom


Twitter

Twitter is close to a big breakout and a rise above $36.75, as I noted in an Investopedia article, sends shares much higher, perhaps to $46. The holder of January 2019 $37 calls, pared their position back yesterday, with the open interest being reduced to 89,000 contracts.  The calls trade at $6.25, and that makes the open contracts worth about $55 million. Whoa! To think it was about $66 million yesterday before they sold some of those calls.

I went over this in the premium video yesterday and showed the build-up in the open interest when I think the position was first purchased.

Again, it surprises me how slow this trader is in lowering the position given the massive gains. In the article I wrote yesterday, I noted the open interest jumped around the end of August, and the price of Twitter was much lower, like in the upper-teens, which means the options were likely bought for a very cheap premium.

It makes me think they see more gains for the stock price.

 

twitter

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 731 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

That is it!

Advertisements


Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free 2 Week Trial

Recent Videos:

Looking At Twitter

More Upgrades On Amazon And Micron

Micron Jumps, Nvidia’s Breakout

Market Surges Breakouts All Over

Roku Borrow Rate Surge, Biotech Fakeout?

Tech And Biotech Look Weak, Plus Subscriber Mailbag

What The Heck Happened

 

Free Articles Written By Mike:

Alibaba Stock May Surge By 11%

Why Broadcom May Rise As Much As 17%

Twitter’s Soaring Stock May Go 25% Higher

Why Visa’s Stock May Rise 14% in 2018

Why Celgene’s Beaten Down Stock Can Rise 28%

Ford Options Traders Bet Stock Will Fall 25% This Year

Biogen’s Bargain Price May Spur a 14% Stock Gain

Qualcomm Poised For 20% Drop After Broadcom Deal Halted

Nvidia’s Breakout Seen Fueling 14% Stock Gain

Why Overvalued Gilead May Fall 10%

3 Chip Stocks Poised to Rise as Much as 26%

Facebook Seen Rising 20% Defying Skeptics

Roku Shares Could Fall 50% Further

Why Micron’s Stock Bulls May Be Wrong

Why Bank Stocks Are Ready for a Short-Term Pullback

 

Join our 731 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo credit via Flickr

Michael Kramer and the clients of Mott Capital own shares of ACAD, TSLA

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #biotech #biogen #regeneron #twitter #amd #broadcom  

Advertisements